FINNENCE ▪ THE WIRE FILE
THE WIRE · № 62180
Company■ Unclear/unknown
New Phase 3 trial: A Study to Evaluate the Efficacy and Safety of Proximod in Patients With Rheumatoid Arthritis — Jiankuan (Suzhou) Biotechnology Company Limited
KINDCompany
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-02 12:00 UTC
LAST UPDATE2026-10-02 12:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A Phase 3 rheumatoid arthritis trial from a Chinese biotech signals pipeline activity but no listed ticker.
Early RA trial, no listed ticker exposure
CATALYST TO WATCH
Trial enrollment and efficacy results
MAIN RISK
Trial may fail or face delays
FULL DISPATCH
Sponsor: Jiankuan (Suzhou) Biotechnology Company Limited; Status: Not Yet Recruiting; Conditions: Rheumatoid Arthrits; Interventions: Placebo, Proximod, Proximod; Enrollment: 590 (estimated); First posted: 2026-10-02; NCT: NCT07856511
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
New Phase 3 trial: SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight — Boehringer Ingelheim2026-10-02 12:00 UTC
New Phase 3 trial: SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight — Boehringer Ingelheim2026-10-02 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD Treatment — Intra-Cellular Therapies, Inc.2026-10-02 12:00 UTC
New Phase 3 trial: A Study of JNJ-99245354 (ITI-1284) as an Adjunctive Treatment in Participants With Generalized Anxiety Disorder (GAD) Who Have an Inadequate Response to GAD Treatment — Intra-Cellular Therapies, Inc.2026-10-02 12:00 UTC
→CORRELATIONshares Healthcare
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike2026-10-02 12:11 UTC
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike2026-10-02 12:11 UTC
→CORRELATIONshares Healthcare
Your health insurance premiums may take a big jump in 2027 — here's why2026-10-02 16:26 UTC
Your health insurance premiums may take a big jump in 2027 — here's why2026-10-02 16:26 UTC
←CORRELATIONshares Healthcare
Supreme Court denies Arizona’s bid to delay start of takeover of healthcare in state prisons2026-10-01 21:42 UTC
Supreme Court denies Arizona’s bid to delay start of takeover of healthcare in state prisons2026-10-01 21:42 UTC
←CORRELATIONshares Healthcare
Lundbeck to showcase progress across its movement disorders pipeline with data in multiple system atrophy and Parkinson's disease at MDS® 20262026-10-02 06:29 UTC
Lundbeck to showcase progress across its movement disorders pipeline with data in multiple system atrophy and Parkinson's disease at MDS® 20262026-10-02 06:29 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.